Oppenheimer Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $230
Veeva Systems Is Maintained at Outperform by Baird
Veeva Systems Analyst Ratings
Baird Maintains Veeva Systems(VEEV.US) With Buy Rating, Cuts Target Price to $245
Barclays Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $240
Analysts Are Bullish on Top Healthcare Stocks: Medpace Holdings (MEDP), Veeva Systems (VEEV)
Wells Fargo Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $242
Wells Fargo Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $242
Buy Rating for Veeva Systems: Leveraging Veeva Link's Innovative Market Intelligence in Pharma
Veeva Systems Analyst Ratings
BNP Paribas Exane Initiates Veeva Systems at Outperform With $286 Price Target
Wells Fargo Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $242
Maintaining a Buy Rating: Veeva Systems' Strong CRM Retention and Competitive Edge Over IQVIA
Veeva Systems Analyst Ratings
Guggenheim Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $249
Morgan Stanley Maintains Veeva Systems(VEEV.US) With Sell Rating, Maintains Target Price $173
Veeva Systems Sell Rating: Competitive and Regulatory Challenges Ahead
Oppenheimer Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $230
Oppenheimer Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $230
Oppenheimer Sticks to Their Buy Rating for Veeva Systems (VEEV)